Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study

Ryosuke Mihara, Kenji Kabashima, Masutaka Furue, Miwa Nakano, Thomas Ruzicka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately controlled by topical treatments in a two-part, phase II, randomized control trial. The Work Productivity and Activity Impairment – Atopic Dermatitis questionnaire was an exploratory end-point. Part A was a 12-week, placebo-controlled study in which patients received s.c. nemolizumab 0.1, 0.5 or 2.0 mg/kg every 4 weeks or 2.0 mg/kg every 8 weeks. Part B was a 52-week extension in which all patients received active treatment. A total of 138 patients had Work Productivity and Activity Impairment – Atopic Dermatitis data; 104 were employed at baseline. At week 12, patients receiving nemolizumab every 4 weeks showed greater mean (standard error) Work Productivity and Activity Impairment – Atopic Dermatitis improvement (score reduction) from baseline versus placebo: Percent Work Time Missed (0.1, 0.5 or 2.0 mg/kg vs placebo): –4.0% (3.9%), –1.7% (4.2%) and –1.6% (4.2%) versus 4.9% (4.5%); Percent Impairment While Working, –15.8% (6.0%), –24.1% (6.5%) and –34.3% (6.4%) versus –16.5% (7.1%); Percent Overall Work Impairment, –16.3% (6.0%), –23.1% (6.5%) and –34.5% (6.3%) versus –16.6% (7.1%); and Percent Activity Impairment, –13.4% (5.3%), –23.5% (5.3%) and –41.9% (5.5%) versus –10.9% (5.7%). Improvements were sustained through week 64. Nemolizumab-treated patients with moderate to severe atopic dermatitis reported improvements in Work Productivity and Activity Impairment through week 64.

Original languageEnglish
Pages (from-to)662-671
Number of pages10
JournalJournal of Dermatology
Volume46
Issue number8
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Atopic Dermatitis
Placebos
Therapeutics

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Nemolizumab in moderate to severe atopic dermatitis : An exploratory analysis of work productivity and activity impairment in a randomized phase II study. / Mihara, Ryosuke; Kabashima, Kenji; Furue, Masutaka; Nakano, Miwa; Ruzicka, Thomas.

In: Journal of Dermatology, Vol. 46, No. 8, 01.01.2019, p. 662-671.

Research output: Contribution to journalArticle

@article{5100944e11ad4fe79e7fc185f7ac1250,
title = "Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study",
abstract = "Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately controlled by topical treatments in a two-part, phase II, randomized control trial. The Work Productivity and Activity Impairment – Atopic Dermatitis questionnaire was an exploratory end-point. Part A was a 12-week, placebo-controlled study in which patients received s.c. nemolizumab 0.1, 0.5 or 2.0 mg/kg every 4 weeks or 2.0 mg/kg every 8 weeks. Part B was a 52-week extension in which all patients received active treatment. A total of 138 patients had Work Productivity and Activity Impairment – Atopic Dermatitis data; 104 were employed at baseline. At week 12, patients receiving nemolizumab every 4 weeks showed greater mean (standard error) Work Productivity and Activity Impairment – Atopic Dermatitis improvement (score reduction) from baseline versus placebo: Percent Work Time Missed (0.1, 0.5 or 2.0 mg/kg vs placebo): –4.0{\%} (3.9{\%}), –1.7{\%} (4.2{\%}) and –1.6{\%} (4.2{\%}) versus 4.9{\%} (4.5{\%}); Percent Impairment While Working, –15.8{\%} (6.0{\%}), –24.1{\%} (6.5{\%}) and –34.3{\%} (6.4{\%}) versus –16.5{\%} (7.1{\%}); Percent Overall Work Impairment, –16.3{\%} (6.0{\%}), –23.1{\%} (6.5{\%}) and –34.5{\%} (6.3{\%}) versus –16.6{\%} (7.1{\%}); and Percent Activity Impairment, –13.4{\%} (5.3{\%}), –23.5{\%} (5.3{\%}) and –41.9{\%} (5.5{\%}) versus –10.9{\%} (5.7{\%}). Improvements were sustained through week 64. Nemolizumab-treated patients with moderate to severe atopic dermatitis reported improvements in Work Productivity and Activity Impairment through week 64.",
author = "Ryosuke Mihara and Kenji Kabashima and Masutaka Furue and Miwa Nakano and Thomas Ruzicka",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/1346-8138.14934",
language = "English",
volume = "46",
pages = "662--671",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Nemolizumab in moderate to severe atopic dermatitis

T2 - An exploratory analysis of work productivity and activity impairment in a randomized phase II study

AU - Mihara, Ryosuke

AU - Kabashima, Kenji

AU - Furue, Masutaka

AU - Nakano, Miwa

AU - Ruzicka, Thomas

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately controlled by topical treatments in a two-part, phase II, randomized control trial. The Work Productivity and Activity Impairment – Atopic Dermatitis questionnaire was an exploratory end-point. Part A was a 12-week, placebo-controlled study in which patients received s.c. nemolizumab 0.1, 0.5 or 2.0 mg/kg every 4 weeks or 2.0 mg/kg every 8 weeks. Part B was a 52-week extension in which all patients received active treatment. A total of 138 patients had Work Productivity and Activity Impairment – Atopic Dermatitis data; 104 were employed at baseline. At week 12, patients receiving nemolizumab every 4 weeks showed greater mean (standard error) Work Productivity and Activity Impairment – Atopic Dermatitis improvement (score reduction) from baseline versus placebo: Percent Work Time Missed (0.1, 0.5 or 2.0 mg/kg vs placebo): –4.0% (3.9%), –1.7% (4.2%) and –1.6% (4.2%) versus 4.9% (4.5%); Percent Impairment While Working, –15.8% (6.0%), –24.1% (6.5%) and –34.3% (6.4%) versus –16.5% (7.1%); Percent Overall Work Impairment, –16.3% (6.0%), –23.1% (6.5%) and –34.5% (6.3%) versus –16.6% (7.1%); and Percent Activity Impairment, –13.4% (5.3%), –23.5% (5.3%) and –41.9% (5.5%) versus –10.9% (5.7%). Improvements were sustained through week 64. Nemolizumab-treated patients with moderate to severe atopic dermatitis reported improvements in Work Productivity and Activity Impairment through week 64.

AB - Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately controlled by topical treatments in a two-part, phase II, randomized control trial. The Work Productivity and Activity Impairment – Atopic Dermatitis questionnaire was an exploratory end-point. Part A was a 12-week, placebo-controlled study in which patients received s.c. nemolizumab 0.1, 0.5 or 2.0 mg/kg every 4 weeks or 2.0 mg/kg every 8 weeks. Part B was a 52-week extension in which all patients received active treatment. A total of 138 patients had Work Productivity and Activity Impairment – Atopic Dermatitis data; 104 were employed at baseline. At week 12, patients receiving nemolizumab every 4 weeks showed greater mean (standard error) Work Productivity and Activity Impairment – Atopic Dermatitis improvement (score reduction) from baseline versus placebo: Percent Work Time Missed (0.1, 0.5 or 2.0 mg/kg vs placebo): –4.0% (3.9%), –1.7% (4.2%) and –1.6% (4.2%) versus 4.9% (4.5%); Percent Impairment While Working, –15.8% (6.0%), –24.1% (6.5%) and –34.3% (6.4%) versus –16.5% (7.1%); Percent Overall Work Impairment, –16.3% (6.0%), –23.1% (6.5%) and –34.5% (6.3%) versus –16.6% (7.1%); and Percent Activity Impairment, –13.4% (5.3%), –23.5% (5.3%) and –41.9% (5.5%) versus –10.9% (5.7%). Improvements were sustained through week 64. Nemolizumab-treated patients with moderate to severe atopic dermatitis reported improvements in Work Productivity and Activity Impairment through week 64.

UR - http://www.scopus.com/inward/record.url?scp=85067357766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067357766&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.14934

DO - 10.1111/1346-8138.14934

M3 - Article

C2 - 31166620

AN - SCOPUS:85067357766

VL - 46

SP - 662

EP - 671

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 8

ER -